Transcarent vs Ubie (2026)
Both guide people toward the right care, for different buyers. Transcarent sells benefits navigation and care to self insured employers, health plans and unions; its WayFinding experience, a generative AI layer launched in 2024, combines benefits navigation, clinical guidance and care access in one interface, drawing recommendations from a member's own history. Ubie offers a free consumer symptom checker that turns a three minute questionnaire covering about 1,000 diseases into a report on possible causes and when to seek care, and sells Smart Support to medical practices. Choose Transcarent if you are an employer or plan steering members through benefits; choose Ubie for free symptom guidance open to anyone.
- You are a self insured employer, health plan or union.
- Navigation should draw on each member's own history and benefits.
- Guidance should connect members to care inside the same service.
- Anyone should be able to check symptoms free, with no registration.
- A short questionnaire suits your patients.
- Your practice wants the same engine through Smart Support.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Transcarent and Ubie are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Transcarent | Ubie |
|---|---|---|
| Primary category | Healthcare Administrative Automation | Clinical Decision Support |
| Founded | Not recorded | 2017 |
| Headquarters | San Francisco, California | Tokyo, Japan |
| Website | transcarent.com | ubiehealth.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Ubie
-
Regulatory / guideline
Ubie's AI-powered patient access tool, Smart Support, has been officially qualified on the Mayo Clinic Platform.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Health benefits navigation and care platform for self insured employers, health plans and labor unions. WayFinding is a generative AI experience launched in 2024 and scaled through 2025, combining benefits navigation, clinical guidance, and care access in one interface, delivering tailored recommendations from a member's own history so a member can determine what is covered, what it will cost, and where to go.
Source: AI Health Index, September 2026
Japanese health technology company with two AI products. The free consumer symptom checker generates a report on possible causes and when to seek care from a roughly three-minute adaptive questionnaire covering about 1,000 diseases, built on more than 50,000 publications, supervised by more than 50 named physicians and refined on real-world data from more than 1,700 providers.
Source: AI Health Index, September 2026
Questions buyers ask
How do Transcarent and Ubie work with the EHR?
For Transcarent, the health plan page describes pre built connectors to common benefits solutions, HL7 FHIR and EDI capabilities, and alignment with CMS interoperability standards, and the company says the platform integrates with an employer's medical and pharmacy benefits and point solutions.
With Ubie, the consumer checker does not integrate with records: patients take a report or doctor's note to their clinician. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How are Transcarent and Ubie priced and sold?
In Transcarent's case, the 2025 merger bundled two previously separate purchases, a navigation platform and a large advocacy and clinical services organization, and those components price very differently: a software interface and a staffed advocacy service have different cost structures, scaling behavior and renewal dynamics.
For Ubie, the symptom checker is free, with no registration or card. Smart Support, sold to practices and health systems, is priced on usage so cost tracks answered calls, offers a free trial for smaller practices and a one-sheet with pricing on request; set-up takes days, with EHR integration handled by the company. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Which settings and specialties do Transcarent and Ubie cover?
With Transcarent, the range spans navigation, clinical delivery, and benefits administration, and maturity across those is unlikely to be uniform.
In Ubie's case, the consumer checker covers about 1,000 diseases by symptom, disease, body part and specialty, including mental health and women's health, in Japan, the United States and other markets, with algorithms said to be customized by country. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Transcarent and Ubie?
For Transcarent, the company reports more than 21 million members across more than 1,700 employer and health plan clients after the 2025 Accolade merger.
With Ubie, the symptom checker page cites a medRxiv preprint (2024) reporting top 10 accuracy of 71.6 percent on clinical vignettes against about 60 percent for other symptom checkers; vignettes are written cases, not live patients, and the preprint is not peer reviewed. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Patient Voice Agents page.
Both records were reviewed on this site in September 2026. Transcarent publishes no price, and Ubie's checker is free. Both give guidance on the level of care without stating a US regulatory position.
Ask both how their guidance is checked against what clinicians would advise.